Seronegative Myasthenia Gravis - Efgartigimod IV

Summary

This is to study the efficacy, safety and tolerability of efgartigimod in patients with seronegative generalized myasthenia gravis. This is an open label study. There will be 30 participants to enroll at University Health Network Toronto General Hospital. Study duration is 43 weeks from screening to end of study.

Timeline

Start

2023-06-01

Primary completion

2025-05

Completion

2025-05

Publications

• Khateb M, Sivadasan A, Barnett-Tapia C, Daniyal L, Fernando L, Chen S, Lovblom LE, Katzberg H, Bril V. Open-label study of efgartigimod in seronegative myasthenia gravis. Ther Adv Neurol Disord. 2025 Oct 31;18:17562864251388019. doi: 10.1177/17562864251388019. eCollection 2025.

Drugs

Indications